Vietnam: Ban from Ministry of Health vs. Piloting Management from Ministry of Industry and Commerce

Regulations by 2FIRSTS, edited by Sophia
May.05.2024
Vietnam: Ban from Ministry of Health vs. Piloting Management from Ministry of Industry and Commerce
Vietnam debates whether to ban or regulate e-cigarettes due to potential health risks and widespread use among youth.

According to Vietnamese media outlet Viettimes, on May 4th, the issue of whether to ban or regulate e-cigarettes was discussed in the National Assembly by the Social Affairs Committee and the National Assembly's Committee on Cultural Education to address concerns about the harm caused by e-cigarettes and heated tobacco products.

 

Deputy Minister of Health Dao Honglan stated that the Ministry of Health has already done a lot of work, providing advice to the national management through evidence and impact assessment in order to revise the Tobacco Harmful Effects Law and make plans. Minister of Industry and Trade Pan Sheng proposed piloting management of e-cigarettes.

 

Faced with the conflicting views of the Ministry of Health and the Ministry of Industry and Commerce on e-cigarettes, representatives in Congress raised pointed questions.

 

The Vice Chairman of the Vietnamese National Assembly, Tran Thanh Man, expressed concerns about the increasing prevalence of e-cigarette use, especially among young people, teenagers, and students, which are gradually replacing traditional tobacco. He emphasized that the health risks of e-cigarettes are similar to traditional tobacco, particularly the harm they pose to the brain development of children and adolescents, leading to addiction, cognitive and emotional disorders, reduced learning abilities, and psychological obstacles. E-cigarettes also have a negative impact on the quality of human resources, affecting social order and economic and social development.

 

Vice Chairperson of the Cultural and Education Committee, Ms. Ruan Mei, calls for clarity on the boundaries between the economic benefits of e-cigarettes and the negative impacts on health costs.

 

Speaking at the conference, Dr. Nguyen Vinh Chi firmly stated, "I find it strange, why test addictive substances, especially such deadly substances. There is absolutely no need for any testing! Because e-cigarettes have already proliferated globally and in Vietnam, their harm is widely recognized... As a doctor, I question whether anyone can find any benefits of this e-cigarette!"

 

Dao Honglan emphasized that e-cigarettes and heated tobacco products pose great risks to human health, and therefore should be banned from the start rather than being allowed on the market before becoming unmanageable. Even with the various current methods of e-cigarette regulation, the question of whether they can be effectively managed is a concerning issue. Who will be responsible for people's lives? Especially when around 40,000 people die from smoking each year.

 

Deputy Director Chen Ruanquan, of the Legal and Administrative Reform Department of the Ministry of Public Security, shares the same view as the Ministry of Health, believing that e-cigarettes pose a harm to human health, particularly for young people. He maintains that this product not only harms human health but also the economy. In particular, individuals who have been convicted of drug offenses are increasingly using e-cigarettes to soak and mix drugs.

 

Teenage use of e-cigarettes is widespread. People are always seen using e-cigarettes while waiting at red lights on the streets. This trend is growing at a concerning rate, so the harms of e-cigarettes outweigh the expected economic and social benefits, according to Rear Admiral Chen Ruanquan.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana Halts Sales of Elf Bar, Lost Mary, MR FOG and iJOY Vapes Under Foreign-Adversary Rules; Some Products Return After Compliance Filings
Indiana's Alcohol and Tobacco Commission (ATC) ordered tobacco certificate holders in September to remove certain vaping products marketed under Elf Bar, Lost Mary, MR FOG, iJOY and other brands from inventory under the state's foreign-adversary product law. The agency later listed 257 MR FOG products and 77 Lost Mary product entries as lawful for sale. The Lost Mary revision expressly stated that compliance evidence had been received for 20 additional products. 2Firsts compliance expert Kurt said potential filings could include e-liquid and ingredient-origin records, U.S. nicotine-analog supply-chain documentation and FDA premarket application status.
Regulations
Oct.08
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12